Trial Profile

Phase I/II Trial of Human Leukocyte Antigen (HLA)-A 2402-Restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination [pancreatic cancer vaccine] Combined With Gemcitabine for Advanced Pancreatic Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2009 Biomarkers information updated
08 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
10 Jun 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com